NRP1 Antibodies with High Affinity Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective antibodies or antibody fragments that can specifically target and modulate neuropilin 1 (NRP1) with high affinity and specificity, which is crucial for treating various diseases related to NRP1's role in angiogenesis and cancer progression.
Innovation Solution
Development of antibodies or antibody fragments with variable domains that exhibit at least 90% sequence identity to specific sequences, including monoclonal, polyclonal, or humanized forms, which can act as agonists, antagonists, or allosteric modulators of NRP1, with binding affinities below 10 nanomolar, to treat diseases associated with NRP1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then treatment is available for NRP1-related diseases, but the binding affinity and specificity to NRP1 are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody sequence parameters (variable domain sequences, CDR regions, framework regions) to achieve enhanced binding affinity (KD < 10 nM) and specificity to NRP1. Multiple sequence variants with at least 90% identity to reference sequences are provided, allowing selection of parameters that maximize therapeutic effectiveness while maintaining manufacturability.
2Reliability
If antibodies with high binding affinity (KD < 10 nM) are developed, then therapeutic effectiveness is improved, but the complexity of antibody design and characterization increases
Solution Approach 1:
The patent segments the antibody structure into distinct functional regions (variable heavy chain VH, variable light chain VL, complementarity determining regions CDR1-CDR3, framework regions FW1-FW4) that can be independently optimized. This segmentation allows systematic design of high-affinity antibodies by focusing on key binding regions while using standardized framework sequences, thereby managing design complexity.
Solution Approach 2:
The patent provides universal framework sequences and CDR grafting methodologies that can be applied across multiple antibody variants targeting NRP1. The standardized framework regions (FW1-FW4) serve as a universal platform that can accommodate different CDR sequences, reducing the overall complexity of antibody design and characterization by reusing proven structural elements.
3Reliability
If monoclonal, humanized, or synthetic antibody forms are used, then specificity to NRP1 is enhanced, but the manufacturing and regulatory approval process becomes more complex
Solution Approach 1:
The patent provides multiple parameter options for antibody construction including different variable domain sequences, CDR regions, and framework regions that can be selected based on manufacturing capabilities and regulatory requirements. The sequences are designed to maintain high specificity while being amenable to various production platforms (monoclonal, polyclonal, humanized, synthetic).
Solution Approach 2:
The patent provides detailed sequence information and structural blueprints that can be copied and reproduced across different manufacturing processes. The reference sequences (SEQ ID NOs: 1-299 for VH, 300-484 for VL) serve as master templates that can be replicated with high fidelity, ensuring consistency across batches and manufacturing sites while simplifying regulatory approval through demonstrated reproducibility.
Data Source
AI summary
Provided herein are methods and compositions relating to neuropilin-1 (NRP1) libraries having nucleic acids encoding for immunoglobulins that bind to NRP1. Libraries described herein include variegated libraries comprising nucleic acids each encoding for a predetermined variant of at least one predetermined reference nucleic acid sequence. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.